Sunuyu indir
Sunum yükleniyor. Lütfen bekleyiniz
YayınlayanSedef Kayyali Değiştirilmiş 9 yıl önce
1
Kartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi
PERKÜTAN MİTRAL KAPAK TAMİRİ Endikasyonlar ve Klinik Çalışmalar kapak tamir atölyesi 1-2 Kasım 2013, İSTANBUL Dr. Selçuk Pala Kartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi
3
European Heart Journal (2007) 28, 1358–1365
5
EVEREST I (Endovascular Valve Edge-to-Edge Repair)
inclusion criteria All patients were potential candidates for MV surgery symptomatic and/or had compromised LV function(LVEF <60% or LVESD >45 mm). With regard to MR severity, patients met at least three out of six criteria for severity, one of which was quantitative.
7
EVEREST I exclusion criteria
Etiology of MR being infectious or rheumatic LVEF of <30% LVES dimension of >55 mm MV area of <4.0 cm2
8
EVEREST I
17
EVEREST II
18
EVEREST II
19
EVEREST II
20
EVEREST II
21
EVEREST II
22
EVEREST II
23
EVEREST II
25
EVEREST II
26
EVEREST II
27
EVEREST II
28
EVEREST II
32
EVEREST II HRR
33
EVEREST II comparator group (n= 36)
35
EVEREST HRS
36
EVEREST II HRS
37
EVEREST HRS
40
ACCESS EU
45
ACCESS EU
46
ACCESS EU
47
ACCESS EU
48
ESC
50
SUMMARY The MitraClip procedure can be performed safely with low major advers event rate. Beyond 6 months, the rate of MV surgery low in the MitraClip patients
51
SUMARY SURGERY İS the standard of care for treatment of MR among elegible patient
52
SUMMARY Clinical benefits provided by MitraClip is durable through 4 years ** Reduced in MR severity ** İmprovment in LV Dimension ** İmprovments in NYHA Functional Class
53
Conclusion The MitraClip procedure is a therapeutic option for selected patients with significant MR
54
Kartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi
PERKÜTAN MİTRAL KAPAK TAMİRİ Endikasyonlar ve Klinik Çalışmalar kapak tamir atölyesi 1-2 Kasım 2013, İSTANBUL Dr. Selçuk Pala Kartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi
Benzer bir sunumlar
© 2024 SlidePlayer.biz.tr Inc.
All rights reserved.